Abstract:Despite advances in the treatment of acute myeloid leukemia (AML), relapse is still widely observed and represents the major cause of death among patients with AML. Treatment options in the relapse setting are limited, still relying predominantly on allogeneic hematopoietic stem cell transplantation (allo-HSCT) and cytotoxic chemotherapy, with poor outcomes. Novel targeted and venetoclax-based combinations are being investigated and have shown encouraging results. Immune checkpoint inhibitors in combination with low-intensity chemotherapy demonstrated encouraging response rates and survival among patients with relapsed and/or refractory (R/R) AML, especially in the pre- and post-allo-HSCT setting. Blocking the CD47/SIRPα pathway is another strategy that showed robust anti-leukemic activity, with a response rate of around 70% and an encouraging median overall survival in patients with newly diagnosed, higher-risk myelodysplastic syndrome and patients with AML with a TP53 mutation. One approach that was proven to be very effective in the relapsed setting of lymphoid malignancies is chimeric antigen receptor (CAR) T cells. It relies on the infusion of genetically engineered T cells capable of recognizing specific epitopes on the surface of leukemia cells. In AML, different CAR constructs with different target antigens have been evaluated and demonstrated safety and feasibility in the R/R setting. However, the difficulty of potently targeting leukemic blasts in AML while sparing normal cells represents a major limitation to their use, and strategies are being tested to overcome this obstacle. A different approach is based on endogenously redirecting the patient’s system cells to target and destroy leukemic cells via bispecific T-cell engagers (BiTEs) or dual antigen receptor targeting (DARTs). Early results have demonstrated the safety and feasibility of these agents, and research is ongoing to develop BiTEs with longer half-life, allowing for less frequent administration schedules and developing them in earlier and lower disease burden settings.

LYMPHOCYTOTOXIC AND RNA ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: A COMPARATIVE STUDY IN PATIENTS AND THEIR FAMILIES

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia

Polarized packaging of bacteriophage lambda chromosomes.

The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands

Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options

Targeted Treatment of Acute Myeloid Leukemia Based on Epigenetic Regulation Mechanism

Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia

Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia

Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective

Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia

An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!

Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets

Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy

Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia

Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled

The Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia

Present and Future Role of Immune Targets in Acute Myeloid Leukemia

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments

Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors